Cardio-Vascular Pharmacology

Dr. Shadi HOMSI


24-8-2016

β-ADRENOCEPTOR-BLOCKING AGENTS

> β-Blockers are a <u>treatment option</u> for hypertensive patients with concomitant heart disease or heart failure

A. Actions

- \triangleright Selective β1 blockers (metoprolol, atenolol) = most commonly prescribed β-blockers.
- \triangleright *Nebivolol* is a selective β_1 blocker, which also increases the production of nitric oxide, leading to vasodilation.
- Fig. The selective β-blockers may be administered cautiously to hypertensive patients who also have asthma. Whereas The nonselective β-blockers (propranolol and nadolol) are contraindicated in patients with asthma.
- ➤ Can be used in patients with diabetes, peripheral vascular disease, and chronic obstructive pulmonary disease, as long as they are monitored closely.



Actions of β -adrenoceptor-blocking agents.

:

C. Pharmacokinetics

- ➤ Orally active for the treatment of hypertension (may take several weeks to develop their full effects).
- > Esmolol, metoprolol, and propranolol are available in intravenous formulations.
- ➤ Propranolol undergoes extensive and highly first-pass metabolism.

B. Therapeutic uses

- ➤ In hypertensive patients with concomitant heart disease (previous myocardial infarction, angina pectoris, and chronic heart failure).
- \triangleright Conditions that discourage the use of β -blockers include: asthma and severe peripheral vascular disease.
- ➤ Three β-blockers have shown benefit in Heart Failure: **bisoprolol**, **carvedilol**, and long-acting **metoprolol** succinate
- \triangleright Carvedilol is a nonselective β -adrenoreceptor antagonist that also blocks α -adrenoreceptors, whereas bisoprolol and metoprolol succinate are β 1-selective antagonists.
- \triangleright β -Blockade is recommended for all patients with chronic, stable HF
- ➤ Treatment should be started at low doses and gradually titrated to target doses based on patient tolerance and vital signs

.

- \triangleright The β-adrenergic blockers <u>decrease the oxygen demands of the myocardium</u> <u>during exertion and at rest</u> resulting in decreased heart rate, contractility, cardiac output, and blood pressure.
- Can reduce both the frequency and severity of angina attacks.
- \triangleright β -Blockers can be used to increase exercise duration and tolerance in patients with effort-induced angina.
- \triangleright β -Blockers are <u>recommended</u> as initial antianginal therapy in all patients unless contraindicated and [vasospastic angina].
- \triangleright β -Blockers reduce the risk of death and MI in patients who have had a prior MI and also improve mortality in patients with hypertension and heart failure.
- Agents with intrinsic sympathomimetic activity (ISA) such as <u>pindolol</u> should be avoided in patients with angina and those who have had a MI.

D. Adverse effects

1. Common effects:

- \triangleright The β-blockers may cause bradycardia, hypotension, and CNS side effects such as fatigue, lethargy, and insomnia.
- \triangleright β -Blockers should be avoided in patients with severe bradycardia.
- \triangleright The β-blockers may decrease libido and cause erectile dysfunction, which can severely reduce patient compliance.

2. Alterations in serum lipid patterns:

> Nonselective β-blockers may decrease HDL cholesterol and increase TG.

3. Drug withdrawal:

➤ Abrupt withdrawal may induce angina, myocardial infarction, and even sudden death in patients with ischemic heart disease.

-